# Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)

> **NCT04326920** · PHASE4 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 87 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Sargramostim
- **OTHER:** Control

## Key facts

- **NCT ID:** NCT04326920
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-24
- **Primary completion:** 2020-09-28
- **Final completion:** 2021-02-26
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2022-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04326920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04326920, "Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04326920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*